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Abstract
Background: Realising the economic potential of research institutions, including medical research institutes, represents
a policy imperative for many Organisation for Economic Co-operation and Development nations. The assessment of
research impact has consequently drawn increasing attention. Research impact assessment frameworks (RIAFs) provide
a structure to assess research translation, but minimal research has examined whether alternative RIAFs realise the
intended policy outcomes. This paper examines the objectives presented for RIAFs in light of economic imperatives to
justify ongoing support for health and medical research investment, leverage productivity via commercialisation and
outcome–efficiency gains in health systems, and ensure that translation and impact considerations are embedded into
the research process.
This paper sought to list the stated objectives for RIAFs, to identify existing frameworks and to evaluate whether the
identified frameworks possessed the capabilities necessary to address the specified objectives.
Methods: A scoping review of the literature to identify objectives specified for RIAFs, inform upon descriptive criteria for
each objective and identify existing RIAFs. Criteria were derived for each objective. The capability for the existing RIAFs
to realise the alternative objectives was evaluated based upon these criteria.
Results: The collated objectives for RIAFs included accountability (top-down), transparency/accountability
(bottom-up), advocacy, steering, value for money, management/learning and feedback/allocation, prospective
orientation, and speed of translation. Of the 25 RIAFs identified, most satisfied objectives such as accountability
and advocacy, which are largely sufficient for the first economic imperative to justify research investment. The
frameworks primarily designed to optimise the speed of translation or enable the prospective orientation of
research possessed qualities most likely to optimise the productive outcomes from research. However, the results
show that few frameworks met the criteria for these objectives.
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Conclusion: It is imperative that the objective(s) for an assessment framework are explicit and that RIAFs are
designed to realise these objectives. If the objectives include the capability to pro-actively drive productive
research impacts, the potential for prospective orientation and a focus upon the speed of translation merits
prioritisation. Frameworks designed to optimise research translation and impact, rather than simply assess impact,
offer greater promise to contribute to the economic imperatives compelling their implementation.
Keywords: Research impact assessment frameworks, Objectives, Productivity, Medical research, Health research,
Speed of translation, Prospective orientation
Background
The economic potential of research institutions, includ-
ing medical research institutes (MRIs), remains high on
the policy agenda for many Organisation for Economic
Co-operation and Development (OECD) nations [1–4].
As a consequence, the question of how to measure and
assess returns from investment in health and medical
research (HMR) remains a highly policy-relevant issue.
Research impact assessment frameworks (RIAFs) provide
a conceptual framework and methods against which the
translation and impact of HMR can be assessed. Reviews
by the Canadian Academy of Health Sciences (CAHS)
[5], Brutscher [6], Banzi and Moja [7], and Milat and
Bauman [8] summarise in detail the form and character-
istics of existing RIAFs. However, a review of this litera-
ture demonstrates that, despite the centrality of purpose
in evaluation [9], the objective of assessment is rarely
instructive of the form, method and content of these
RIAFs.
Impact assessment of HMR research expenditure has
been elevated on the policy agenda through three inter-
related economic imperatives:
(1)Scarcity – Largely as a result of stimulatory fiscal
policy during the global financial crisis, general
government debt as a percentage of gross domestic
product through 2014, remained markedly higher
than pre-crisis levels for the majority of OECD
nations, including Australia [10]. The accompanying
political pressure to manage this debt, while
simultaneously stimulating economic growth,
heightens the justification necessary for on-going
public expenditure in HMR, against competing
budget priorities.
(2)Productivity – Health service budgets have been cut
or frozen substantially in many OECD nations,
including Australia, intensifying the demand for
innovative research solutions that improve health
outcomes with the same or less public expenditure
[11]. In the commercial realm, economic growth is
increasingly reliant upon a knowledge-intensive
industry, and policymakers are keen to optimise
commercial innovations in medical services,
pharmaceuticals and medical devices [12]. Citing
Australia’s strong research capability, the McKeon
Strategic Review of Health and Medical Research
[13] identified potential productivity gains in both
commercial and non-commercial arenas founded
upon opportunities to leverage HMR and its
supporting ecology. As a consequence, the
requirement to generate economic productivity via
greater commercial returns and cost-effective
improvements to health outcomes represents a
second imperative for impact assessment.
(3)Efficacious, effective and cost-effective research
outcomes – The third economic imperative arises
from within HMR. An increasing level of research
on HMR has highlighted numerous areas of
unproductive expenditure via practices ranging from
poorly-informed research questions and weak study
design to irreproducible outcomes and failed
implementation [14–17]. Chalmers and Bracken [14]
estimate that, globally, $240 billion of annual
biomedical research expenditure is wasted. Their
research illustrates the potential to improve
productive health outcomes by ensuring that
translation is embodied throughout the research
process.
We contend that these imperatives necessitate pri-
oritisation of a different set of objectives, with ac-
cording implications for the impact assessment of
Australia’s MRIs.
Australia supports approximately 70 independent
MRIs, which collectively facilitate the investigations of
approximately 10,100 researchers [18]. The Institutes’ re-
lationship with researchers varies from direct employ-
ment to facilitation of research conducted by employees
of affiliated organisations, such as local health districts,
universities or the private sector. The breadth of HMR
conducted within Australia’s MRIs is extensive, ranging
across populations, disease, policy, practice and medical
products [19], and from basic science through to public
health. The Institutes receive funding through competi-
tive grants, fellowships and programs, state government
infrastructure programs, grants from foundations and
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trusts, and commercial returns from intellectual prop-
erty, contracted research and community donations. In
addition to preferential taxation status, government
support comprises approximately half of this funding
[18]. To justify this support from government and the
community, Australia’s MRIs continue to progress their
approach to impact assessment. This research seeks to
inform upon the development of assessment frameworks
for MRIs.
The first aim of this paper was to list the stated objec-
tives for RIAFs. The second aim sought to identify existing
frameworks. The final aim sought to evaluate whether the
identified frameworks possessed the capabilities necessary
to address the specified objectives.
The definitions adopted for this paper include:
 Research activity – Activities necessary to conduct
medical and health research, where research is
defined as “creative work undertaken on a systematic
basis in order to increase the stock of knowledge,
including knowledge of man, culture and society, and
the use of this stock of knowledge to devise new
applications” [20].
 End-users – Agents along the pathway to impact
that utilise the research outputs, including members
of the community, the public sector, industry and
other researchers. As such, this definition includes
both interim and final users.
 Research outputs –The knowledge deliverables
produced by research activity, e.g. peer-reviewed
papers, presentations, contributions to collaborative
endeavours, guidelines, education, prototypes, etc.
 Research outcomes/Interim impacts – Research
outputs transform to research outcomes/interim
impacts following utilisation by an end-user along
the pathway to final impact.
 Final impacts – The demonstrable effect from the
flows of knowledge between basic, patient and
population-orientated research, and clinical trials,
that improves human health and quality of life,
and generates benefits for society, the economy,
culture, national security, public policy, or the
environment [21].
Methods
The methods for this study are summarised in Fig. 1.
We undertook a scoping review of the literature [22].
The review comprised a systematic search of a finite
number of key publication databases, a rigorous review
of the grey literature and extensive hand searching of
cited references [23, 24] (Fig. 2).
The literature search strategy included a search of peer-
reviewed academic literature held within Scopus and grey
literature referenced within OpenGrey, WHOLIS (Who
Database), WorldWideScience.gov and Science.gov. The
databases were searched using the following strategy:
 KEY ((translation* W/1 (research OR knowledge))
OR “knowledge mobili?ation*” OR “research into
practice” OR “translation to health application*” OR
“translation to patient*” OR “translation to health
practice*” OR “translation to population health
impact” OR “research impact” OR “knowledge into
practice” OR “populari?ation of research” OR
“research generated knowledge”) AND
 TITLE-ABS-KEY (metric* OR framework* OR
payback OR “social return” OR sroi OR measure* OR
“financial return*” OR “political impact” OR “policy
impact*” OR “Social impact*” OR bibliometrics OR
econometrics OR “economic evaluation*” OR “cost
effectiveness” OR “cost benefit analysis”)
The search was limited to studies published in English
from January 2005 to June 2015. Studies not focussed
upon medical or health research were excluded. Only
papers that referred to theory, a conceptual model or
Fig. 1 Flow diagram – Methods
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framework pertaining to the evaluation of research
outcomes were included. Studies that solely examined
bibliographic impact were excluded. Frameworks to
encourage best practice through guidelines/checklists
and assessments focussed upon a singular medicine or
health research area without reference to the utility of
the framework were also excluded.
The results of the search strategy and the exclusion
criteria are summarised in Fig. 2. In summary:
 An initial review of abstracts against the inclusion
criteria in the databases of academic publications
found 1971 abstracts.
 Searches of reference lists and the grey literature
identified a further 67 documents.
 The review of full papers and documents identified
two reviews, 25 frameworks and 26 documents
containing relevant information.
 A number of frameworks represented minor
variations upon an established framework and
were excluded. For example, the Banzi and Moja
[7] framework was considered similar to the
original CAHS [5] framework, and that of Rubio
and Schoenbaum [25] similar to the Trochim and
Kane [26] framework for the purpose of this
analysis.
Fig. 2 Flow diagram – Literature selection protocol [59–62]. *Note: Excludes reviews presented prior to an included framework
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The first aim was realised through a thematic synthesis
of the literature to identify specified objectives and com-
mon criteria. The objectives were identified independ-
ently by two researchers. Criteria for each objective were
derived and independently reviewed by a second re-
searcher. The existing RIAFs were also identified from
the literature by two researchers. For this purpose, a
RIAF was defined as a conceptual model/framework
and/or a collection of evidence designed to assess the
translation or impact of HMR beyond traditional aca-
demic outcomes.
The second aim was realised through identification of
existing research impact assessment frameworks from the
literature search. The final aim was realised through an
evaluation of the respective capabilities of the identified
frameworks. Two researchers independently assessed the
capacity of each RIAF to meet the alternative objectives
based upon the descriptive criteria. The evaluation results
were categorised according to the following exclusive
definitions:
 Yes/No – The RIAF could/could not meet the
criteria specified for each respective objective;
 Partial – The RIAF could meet the criteria for the
respective objectives, but was not relevant to the full
spectrum of HMR; or
 Possible – The RIAF is capable of meeting the
specified criteria for the respective objectives with
modest adaptions
Given that the evaluators possessed significant know-
ledge regarding RIAFs and that guesswork was unlikely, a
percentage agreement statistic was used to test inter-rater
reliability. Following the initial review, inconsistencies
were discussed and a mutually-agreed outcome deter-




The thematic analysis of the literature identified eight cat-
egories under which the objectives for a RIAF could be
grouped (Table 1), namely accountability (top-down);
transparency/accountability (bottom-up); advocacy; steer-
ing; value for money; management/learning and feedback/
allocation; prospective orientation; and speed of transla-
tion. Accountability for the consumption of resources and
the consequences of HMR represents the most common
objective for impact assessment [6]. However, the question
of ‘to whom is the research accountable’ generates differ-
ent implications. A RIAF that provides accountability for
aggregate HMR expenditure on a broad national or
sectoral scale, may provide sufficient information for gov-
ernment or national funders, but insufficient information
for accountability by individual institutions or research
programs. An objective to provide transparency [1] is
closely aligned with accountability at a more granular
level. Transparency to research activity, outputs and out-
come steps along a pathway to impact provides account-
ability for these steps and consequently, the potential to
improve outcomes. Hence, for the purpose of the subse-
quent evaluation, these objectives were separated into ac-
countability (top-down) and transparency/accountability
(bottom-up) with according criteria.
Advocacy was also commonly presented as an object-
ive for research assessment [5]. While the audience for
Table 1 Categories of objectives identified for research impact assessment frameworks (RIAFs)
Objective Review criteria/criterion for RIAFs
Accountability (top-down) Provides information that could be utilised to provide accountability for research impact at an aggregated
national, state or sector level for government, funding bodies or community stakeholders
Transparency/Accountability
(bottom-up)
1. Provides transparency to the research activity, outputs and outcome steps along the pathway to impact
2. Provides information that could be utilised to provide accountability for research at smaller units of
aggregation, e.g. research projects, research programs, individual institutes
Advocacy Provides a demonstration of capability for relevant stakeholders
Steering Capacity to align the research agenda towards a specific target, e.g. improving the diagnosis, treatment and
care of people with dementia
Value for money The outcomes enable broader comparison through standardisation into Quality-Adjusted Life Years,
Disability-Adjusted Life Years, other comparable health outcomes, monetised benefits, employment or similar
Management/Learning and
Feedback/Allocation
Capacity for the information produced by the RIAF to inform subsequent strategic management decisions
within or between research organisations, potentially including fund allocation
Prospective orientation 1. Capacity for a framework to be implemented prospectively
2. Compels prior determination of the potential final impact and the pathway to this goal
3. Incorporates process metrics that allow for prior scrutiny of the anticipated steps towards impact
Speed of translation 1. Compels prior determination of the potential final impact and the pathway to this goal
2. Contains process metrics that enable individual actors (researchers, teams) to be accountable for steps
on the pathway towards final impact
3. Includes a logic model component that necessitates ‘use’ for an outcome to be acknowledged
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advocacy includes politicians, funders, policymakers,
philanthropists, researchers and the wider community,
the implications for RIAFs remain largely consistent.
Consequently, the criterion adopted for advocacy reflects
the ability of a RIAF to demonstrate capability to rele-
vant stakeholders.
The capacity for a framework to steer research to
address specific HMR goals represents a less common
objective [6, 27]. All impact frameworks steer research
towards societal benefits, but not all are designed to
align the research agenda towards a specific target, e.g.
improving the diagnosis, treatment and care of people
with dementia. For example, a framework that solely uti-
lises a case study methodology is ill-placed to realise this
objective [28]. In the subsequent evaluation, the capacity
for a framework to align the research agenda to a
specific target represents the criterion for a Steering
objective.
Value for money is commonly inferred as an objective
for research assessment, but rarely raised explicitly in
the literature [29, 30]. It is possible to define value for
money as the proportion of non-monetised outcomes to
inputs (resources consumed). However, if the informa-
tion from a RIAF seeks to encourage productivity,
broader comparison through standardisation into utility
measures, such as Quality-Adjusted Life Years, other
comparable health outcomes, monetised benefits or
similar would be necessary [31]. The criterion for the
evaluation reflects this requirement.
Learning and feedback represents a common objective
in the literature, while general management was occa-
sionally specified. Funding allocation represents another
related, but less common objective [32]. Given that
financial allocation is dependent upon sufficient man-
agement/learning and feedback information, these three
objectives were collated. The criterion determined for
the evaluation reflected the capacity for the information
produced by the RIAF to inform subsequent strategic
management decisions, such as fund allocation, within
or between research organisations.
The final two objectives are less commonly identified
in the literature. Evaluating the United States National
Institute of Health Clinical and Translational Science
Awards funding, Trochim and Kane [26] specify the
length of time for research translation as a definitive ob-
jective. An objective to improve the speed of translation
seeks to expedite health improvements and closely aligns
with the economic rationale of rates of return, in this
case from HMR investment. To realise improvements in
the length of time for translation, the assessment frame-
work requires three elements. Firstly, identification of
the intended final health impact and where the research
lies along the pathway to this potential impact. Secondly,
the inclusion of process metrics that enable individual
actors (researchers, teams) to be accountable for steps
along the pathway to final impact. Thirdly, the inclusion
of a logic model component that necessitates ‘use’ for an
outcome to be acknowledged as generating an interim
impact. The criteria to assess whether a framework has
the capacity to pro-actively improve the speed of transla-
tion are subsequently determined by these qualities.
The objective of prospective orientation of research is
explicitly raised by the Hunter Medical Research Insti-
tute Framework to Assess the Impact from Translational
Health Research (HMRI FAIT) framework [21] as pro-
spective implementation supports the use of perform-
ance monitoring and feedback. This objective is closely
aligned with the speed of translation, as productive ad-
justments can be made prior to resource expenditure
[21]. However, these themes have been kept discrete as
an objective to improve the speed of translation may
imply requirements beyond prospective implementation
and vice versa. The criteria for this latter objective
reflected the capacity for a framework to be imple-
mented prospectively, whether it compelled prior deter-
mination of the anticipated final impact and whether it
allowed for prior scrutiny of the anticipated steps
towards this goal via process metrics.
Identification of existing RIAFs
The review identified 25 RIAFs that met the literature in-
clusion criteria (Table 2). While inclusion was narrowly
focussed upon frameworks pertaining to the evaluation of
research outcomes, the focus, conceptual form and
methods utilised varied markedly. The breadth of methods
utilised by these frameworks include pure metrics, such as
the engagement and impact framework proposed by
Australian Academy of Technology and Engineering [33],
pure economic models [34], and mixed methods utilised
by CAHS [5], through to the peer-reviewed case studies of
the United Kingdom’s Research Excellence Framework
(REF) [28, 35]. Some frameworks are focussed upon par-
ticular aspects of translation, such as that of Landry and
Amara [36], while others seek to address the research
process across the translation spectrum [26, 37]. Collected
reviews of the form and content of these frameworks have
been published elsewhere [6–8, 38].
Framework evaluation
This study sought to evaluate the capacity of the identi-
fied frameworks to realise the criteria specified for each
objective; the results of this evaluation are summarised
in Table 2. The initial percentage agreement statistic for
the classification of each framework measured 62.5%
between the two independent researchers. Following dis-
cussion of the differences and reclassification, the agree-
ment statistic measured 92%. Where differences remain
unresolved, both responses are tabulated. Differences
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largely reflected moderate variations in the interpret-
ation of the capabilities of the conceptual models. Note
that some frameworks are capable of realising objectives
beyond those specified in their development.
Accountability (top-down)
The majority of existing RIAFs met the criteria to provide
information that could be utilised to provide holistic (top-
down) accountability for government, funding bodies or
community stakeholders. Frameworks classified as ‘partial’
provided few aggregations, e.g. Six-sigma/lean model, or
limited breadth, e.g. Research Utilization Framework, the
Australian Research Council’s Excellence in Research
Australia (ARC ERA) impact measures.1 The form of this
information varies across peer-reviewed qualitative studies
of impact [36, 39, 40], exclusively quantitative analyses
[26, 33, 34, 41–44] and numerous mixed method assess-
ments [5, 21, 27, 45–47].
Transparency/accountability (bottom-up)
Under this criterion, at least 18 frameworks provide suf-
ficient transparency to determine a level of (bottom-up)
accountability to a range of stakeholders. Frameworks,
such as the Economic Impact Analysis (EIA), provide no
transparency below the national or sectoral scale of ana-
lysis and consequently cannot incentivise research activ-
ity [41]. The Australian Academy of Technology and
Engineering’s Research Engagement for Australia frame-
work provides no transparency to non-commercial/non-
financial impacts. It was consequently categorised as
‘partial’, given the limited incentive provided to drive
economic productivity within the public health or not-
for-profit sectors [33].
Advocacy
Nineteen of the frameworks reviewed provide information
suitable for advocacy and a further three frameworks are
partially suitable. Only the Balanced Scorecard and Six-
sigma/lean models are potentially limited, due to their
focus upon performance indicators at the expense of ag-
gregate capability. Frameworks that incorporate a case
study method potentially have an advantage for advocacy
purposes. The narrative can assist the comprehension of
specialist users (policymakers, clinicians), as well as
non-specialists (politicians, funding bodies, philanthro-
pists, the community), and potentially captures impacts
missed by other methods [7]. Case studies are, however,
limited for other objectives by selection, conceptualisa-
tion and reporting bias [40].
Steering
Steering the research agenda was explicitly raised as an
objective for one framework [27] and one of the reviews
[6]. All impact frameworks steer research, directly or
indirectly, towards societal benefits. Whether a frame-
work could align the research agenda towards a specific
target, e.g. improving the diagnosis, treatment and care
of people with dementia, represented the criteria for as-
sessment. The Measurement of Research Impact and
Achievement (MORIA) framework2 provides a prospect-
ive assessment, where the research proposal could be de-
signed and prospectively assessed against the realisation
of the targets for tied funds [48]. The focus upon out-
comes within the Weiss framework also suggests that a
logic model approach could be readily adapted to this
objective [49]. In contrast, some frameworks, such as
ARC ERA, EIA and the REF, are designed for retrospect-
ive analysis and consequently lend themselves poorly to
steering [28, 35, 41, 50]. Finally, a number of the frame-
works could accommodate the pre-specification of a
health ‘target’ [21, 46, 51, 52]. For example, the Decision
Making Impact Model explicitly considers the source of
the demand for research knowledge, from which impact
assessment through the ‘user-pull’ method could be con-
ducted [27].
Value for money
The capacity for the assessment frameworks to realise
the value for money objective is mixed. Only eight
frameworks definitively have the capacity to provide in-
formation to assess value for money. Most of these
frameworks are relatively broad in scope and, conse-
quently, include methods that could provide value for
money assessments, e.g. economic assessment. It is as-
sumed for this assessment that macroeconomic impact
assessments [34, 41] only provide for international or
disease burden comparison and are consequently classi-
fied as partial for the purpose of a value for money ob-
jective. Nearly half of the frameworks were categorised
as ‘partial’ or ‘possible’, alluding to two factors. Firstly,
there is a lack of clarity regarding the purpose and there-
fore for the definition of value for money. Secondly,
ambiguities often remain with the question of ‘value for
money to whom?’.
Management, learning, and feedback and allocation
The majority of frameworks met this criteria, albeit that
the emphasis varies from the relative impact of research
outputs [5, 44, 45, 51] to organisational aims, such as
progress towards strategic goals [32, 53]. While the
methodologies adopted within the frameworks varied,
most provide the grounds to facilitate comparison, albeit
that greater transparency assists comparison in the
“doing, diffusion and impact of research within and
across research fields” [40]. A number of the frameworks
were utilised as the managerial basis for disbursement of
research funds [1, 32, 39, 53].
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Speed of translation
When evaluated against the specified criteria, very few
frameworks are designed to optimise the speed of trans-
lation (Table 2). The Process Marker Model, the Re-
search Utilisation Ladder and the Decision Making
Impact Model were designed with the pathway to impact
and end-users in mind [26, 27, 36]. The latter two are,
however, limited by their focus solely upon final end-
users of research. If imperatives, such as the lag to final
impact [5, 28, 44] and sub-optimal research practices
within HMR [14–17], are to be addressed, then a frame-
work requires a broader interpretation of steps in the
process of research translation. The Balanced Scorecard
represents another performance management framework
that provides for steps along the pathway to impact, but
fails to guide the critical link to usage at each step [42].
The Lean/Six-sigma models incorporate ‘customer’
needs, but favour technical and precisely quantifiable
systems. The Reach Effectiveness Adoption Implementa-
tion Maintenance (RE-AIM) model was developed for
public health programs [54]. Consequently, while logic
model components relating to the adoption, implemen-
tation and maintenance of research interventions em-
phasise usage, RE-AIM does not readily extend to
similar aspirations for biomedical, clinical efficacy or
health systems research. The University of Washington
Institute for Translational Health Sciences Kellogg Logic
Model – World Health Organization Health Services
Assessment (ITHS KLM–WHO) model, fulfils the cri-
teria, but the emphasis upon outputs and a passive ap-
proach to feedback does not provide for the pro-active
acceleration of translation [47]. The characteristics of
HMRI FAIT, the Process Marker Model and Transla-
tional Research Organizations Performance Model ap-
pear most capable of realising this objective. While
limited in some respects, the Decision Making Impact
Model, Lean/Six-sigma, RE-AIM and the Research
Utilization Ladder also possess qualities that are inform-
ative for the realisation of this objective.
Prospective orientation of research
Similar to the speed of translation, the capacity for
frameworks to realise an objective to prospectively
orientate research is mixed (Table 2). Inflexible retro-
spective formats disqualify the existing ARC ERA, EIA,
Matrix Scoring System and the Research Engagement
for Australia [29, 33, 41, 50, 53]. The Health Services Re-
search Impact Framework and the Research Impact
Framework were designed partly to guide researchers in
the prospective planning of research implementation
[40, 51], but provide limited guidance regarding process
metrics that align research to anticipated impacts.
MORIA was developed with a consideration to ‘drive de-
sirable behaviours’ [48]. The intended implementation of
this framework at the grant review stage provides for the
prior orientation of research to optimise productive re-
search outcomes. However, MORIA was focussed upon
the track record of the researcher, as opposed to the re-
search process. Consequently, the specified metrics do
not provide flexibility to tailor interim targets (process
metrics) in line with individual pathways to impact. This
stated, the track record provides an incentive for re-
searchers to realise potential impacts.
Prospective implementation of the HMRI FAIT frame-
work on a number of research programs, including
National Health and Medical Research Council Centres
of Research Excellence, has successfully contributed to
shaping research activity regarding the purpose, focus,
viability, intended outcomes and, potentially, the research
methods adopted to undertake the respective research
[21]. This implementation demonstrates the capacity for
many similar frameworks, such as Payback, the Balanced
Scorecard, the Translational Research Organizations
Performance Model, the Comprehensive Research Metrics
model, the ITHS KLM–WHO model, the RE-AIM model
and REF to develop this capability, given their shared
characteristics [28, 42, 44, 45, 54, 55].
Discussion
Health and medical research conducted under the um-
brella of MRIs has a substantial impact beyond trad-
itional academic outputs. RIAFs provide a mechanism to
both demonstrate and encourage such impacts. This
paper examined the objectives presented for research
impact assessment in light of economic imperatives to
justify on-going government support for HMR invest-
ment, leverage productivity via commercialisation and
outcome-efficiency gains in the health system, and
embed translation and impact into the research process.
The research found that many frameworks do not have
an explicit purpose, nor are they systematically designed
to realise these imperatives or other objectives, despite the
relevance of purpose to their form, method and content.
A potential reason for this omission lies in the hegemony
of the ‘4A’ objectives of accountability, advocacy, analysis
and allocation, presented in formative work by the RAND
Corporation [38, 56]. Whether these objectives are explicit
or implicit, the majority of the evaluated frameworks
possess the capability to provide information for account-
ability, advocacy and strategic management decisions, i.e.
analysis and allocation, to varying degrees. Collectively,
they provide sufficient information to address the initial
imperative to justify investment and provide for gradual
improvement. This research sought to question whether
the objectives included in ‘4A’ are sufficient to address the
other imperatives, and specifically whether the objectives
can be expanded to pro-actively encourage research im-
pact in line with the latter two imperatives.
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To the extent that Management Learning and Feedback
seeks to inform upon the allocation of funds, such as the
United Kingdom REF [35] and MCRI’s Research Perform-
ance Evaluation Framework [32], or the refinement of
subsequent research activity, then most frameworks are
indirectly concerned with accelerating translation and
improving the productive impact of HMR. The main chal-
lenge with retrospective reviews relates to the time lag in
these decisions. Retrospective reviews of research projects,
programs or grants, such as the United Kingdom REF
process typically take 12 months [35], if not years, for the
feedback to actively inform research decisions. For regular
evaluations, it is possible that expectations of the review
will prospectively shape practice and consequently accel-
erate translation. However, the speed of translation will
only be optimised if decisions to improve research transla-
tion and impact are made prospectively; that is, during the
research process. When reviewed against the criteria for
prospective implementation or speed of translation, many
of the frameworks were either insufficient to meet this
requirement or, while capable of adaption, were not de-
signed for this purpose. Even where a pro-active objective
is noted, other priorities can dilute the effect. For example,
the United Kingdom’s REF [28, 35] sought to encourage
research impact, but the adopted method (peer-reviewed
case studies) was ultimately informed by pragmatic
considerations of assessment across multiple disciplines,
rather than the need to drive productive outcomes.
The potential implications for the development of
new or evolved RIAFs for MRIs are numerous. First,
the primary objective/s for a framework should be
made explicit. Second, the framework should be de-
signed to realise these objectives. Third, the qualities of
existing frameworks inform upon the guiding principles
necessary to realise different objectives. If the objective
is to encourage productive research outcomes through
greater integration of translation and impact consider-
ations into the research process, then prospective im-
plementation and a focus upon the speed of translation
merits prioritisation [57].
The limitations of this study include the scoping litera-
ture review methodology, which may not have captured
all potentially relevant studies. Inclusion of the know-
ledge exchange/translation literature and hand-searching
of references should have ensured that the majority of
key documents were captured. The focus upon frame-
works applied to HMR may also have excluded relevant
research with implications for the generalisation of the
conclusions beyond health research. The main limitation
relates to the evaluation. While mitigated by the inde-
pendent review process, the determination of the criteria
and the evaluation of frameworks according to these
criteria introduces subjectivity as to the capabilities of
each RIAF. However, modest subjective differences in
categorisation should not act to undermine the over-
arching conclusion regarding the disconnection between
the capabilities of most existing RIAFs and the economic
imperatives driving their development and implementa-
tion. Inclusion of a third reviewer may have strength-
ened the research design, but was precluded by resource
constraints.
These issues raise a number of additional questions. If
the objective is to optimise research translation and im-
pact, consistent with the economic imperatives to drive
productive gains, then where should a framework be im-
plemented? At one or more points through the research
process or at the institutional level? Through academic
track records or the research process? How would such
a framework fit with the peer-review process? The value
of a RIAF integrated with the research process would be
that it acts less as an additional administrative burden
upon researchers, and more as an enabling mechanism
for researchers to demonstrate and optimise the transla-
tion and impact of their work. What would the attitude
of researchers be to such an approach? Is it viable in
practice? Questions of to whom, within what time-
frame, of causality and attribution, also remain a chal-
lenge [5, 28, 40, 44]. How would a framework address
these issues? If the primary challenge is to change re-
search culture, is a resolution to these issues necessary
or merited? What does this imply for the form and posi-
tioning of a framework? Are motivations and incentives
correctly aligned to realise the intended objectives? How
would a more comprehensive researcher-focussed frame-
work fit with national engagement and impact assessment
frameworks, such as the United Kingdom REF [28] or the
framework under development by the Australian Research
Council [30]? This research represents the first in a suite
of research papers that seek to define a draft RIAF for
Australia’s MRIs. These questions need to be addressed in
subsequent research.
Conclusions
Significant expenditure has been incurred developing
RIAFs, both in Australia and internationally. Greater re-
sources will be consumed conducting research transla-
tion and impact assessments using such frameworks.
Consequently, it is vital that these frameworks have the
capacity to deliver upon their intended purpose.
This study demonstrates that, despite the centrality of
purpose to evaluation, insufficient attention has been
placed upon the question of ‘why?’. The main objective/s
for a framework should be explicit and assessment frame-
works should be explicitly designed to realise these objec-
tives. The majority of RIAFs meet the objectives to provide
accountability, and to varying degrees, advocacy and man-
agement learning and feedback. This capacity is adequate
to address the first economic imperative to justify
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investment in HMR, but insufficient to optimise the
actions, outcomes and impacts demanded by the second
(leverage productivity) and third (quality improvement) eco-
nomic imperatives. To address these imperatives, the cap-
acity for a framework to be implemented prospectively and
a focus upon the speed of translation merits prioritisation.
Endnotes
1At the time of writing, the Australian Research Council
were undertaking a consultation process to develop an ex-
plicit Engagement and Impact Assessment framework that
will provide more comprehensive information than con-
tained with the existing Excellence in Research Australia,
which is primarily a research quality framework.
2Measurement of Research Impact and Achievement
was piloted, but not fully implemented, by the Australian
National Health & Medical Research Council.
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